Figure 10. ADI-PEG 20 reduces CT26 tumor growth and prolongs survival as a single agent and in combination with anti-mPD-L1 mAb.

CT26 cells were implanted into Balb/c mice and the next day the mice were treated with 12 mg/kg of ADI-PEG 20 BIWx5W IM, 10 mg/kg anti-mPD-L1 Q2D x 5W IP, 12 mg/kg of ADI-PEG 20 IM BIWx5W and 10 mg/kg anti-mPD-L1 IP Q2D x 5W or vehicle (PBS) control. Tumor Volume (A), body weight (B) and survival (C) were assessed over time.